title: Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
abstract: Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regimen had a 41% (9/22) overall response rate compared with 48% (13/27) for the MEP plus carboplatin (C-MEP) regimen (Chi-squared test, P=0.602). Among 38 CHOP-resistant patients, however, the overall response rate to C-MEP [42% (10/24)] was significantly superior compared with MEP [7% (1/14)] (P=0.023), and the overall survival to C-MEP was superior compared with MEP (P=0.088). Taken together, our results, although non-randomized, suggest that a combination of MEP with carboplatin is better than MEP alone in CHOP-resistant diffuse large B-cell lymphomas.
authors.affiliation: First Department of Internal Medicine, Saitama Medical School, Morohongo 38, Moroyama-machi, Iruma-gun, Saitama 350-0451, Japan. murohashi-ikuo@spu.ac.jp
authors.forename: Ikuo
authors.initials: I
authors.lastname: Murohashi
authors.forename: Takuya
authors.initials: T
authors.lastname: Kashimura
authors.forename: Kazunori
authors.initials: K
authors.lastname: Tominaga
authors.forename: Daisuke
authors.initials: D
authors.lastname: Wakao
authors.forename: Takashi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Miki
authors.initials: M
authors.lastname: Akiba
authors.forename: Kuniya
authors.initials: K
authors.lastname: Kishimoto
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yoshida
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Yagasaki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Itoh
authors.forename: Tohru
authors.initials: T
authors.lastname: Sakata
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Kawai
authors.forename: Katsurou
authors.initials: K
authors.lastname: Itoh
authors.forename: Toshiya
authors.initials: T
authors.lastname: Suzuki
authors.forename: Akira
authors.initials: A
authors.lastname: Matsuda
authors.forename: Kunitake
authors.initials: K
authors.lastname: Hirashima
authors.forename: Masami
authors.initials: M
authors.lastname: Bessho
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D018432:Drug Resistance, Multiple; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D008942:Mitoxantrone; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate